HCP Connect Clinical Author
Dr. Simran Kohli
Specialty
Infectious Diseases
Clinical Updates
19
Experience
4 Years
Author Biography
About Dr. Simran Kohli
Dr. Simran Kohli is an infectious-diseases physician with 4 years of clinical experience. She earned a DM in Infectious Diseases after an MD in General Medicine, focusing on antimicrobial stewardship and HIV care. She follows the challenge of antimicrobial resistance with particular concern. Her writing keeps clinicians updated on emerging infections and therapies.
WHO VSN Registry
Vaccine Safety Monographs
9 monographs
Chickenpox (Varicella) Safety Monograph
Institutional safety information on varicella vaccines. Clinical data for Varivax and ProQuad, side effect profiles, and long-term surveillance metadata.
COVID-19 Protocol Safety Monograph
Evidence-based safety protocols and clinical data for COVID-19 immunizations. Unified registry info from CDC and WHO sources.
Hepatitis B Safety Monograph
Comprehensive clinical safety data for Hepatitis B vaccines. Registry details for single-antigen and combination formulations, newborn protocols, and surveillance metadata.
MMR (Measles, Mumps, Rubella) Safety Monograph
Evidence-based safety information on MMR vaccines for measles, mumps, and rubella. Clinical safety data, side effects, and long-term surveillance metadata.
Meningococcal Safety Monograph
Professional safety data on MenACWY and MenB vaccines. Clinical trial outcomes, manufacturer packages (Menactra, Menveo, Bexsero), and long-term surveillance.
Mpox (Orthopoxvirus) Safety Monograph
Institutional safety information on Mpox (JYNNEOS) vaccines. Clinical safety data, side effects, risk-based eligibility, and monitoring protocols from CDC and WHO sources.
Pneumococcal Safety Monograph
Institutional safety data for pneumococcal vaccines (PCV13, PCV15, PCV20, PPSV23). Clinical monitoring, manufacturer profiles, and adverse event surveillance.
Shingles (Zoster) Safety Monograph
Institutional safety information on Shingrix and Zoster vaccines. Clinical data, reactogenicity profiles, and long-term surveillance metadata for adults 50+.
Smallpox (Biodefense) Safety Monograph
Institutional safety information on Smallpox (JYNNEOS, ACAM2000) vaccines. Clinical safety data, side effects, biodefense protocols, and monitoring.
Published Work
Recent Clinical Updates
19 articles
Infectious Disease
FDA Approves ZAYNICH for cUTI: 89.0% Test-of-Cure in Trial 1
FDA approves cefepime and zidebactam (ZAYNICH) for cUTI including pyelonephritis; Trial 1 showed 89.0% test‑of‑cure vs 68.4% with meropenem.
Infectious Disease
FDA Approves Rezafungin for Candidemia/IC: Day 30 Mortality 23.7% vs 21.3%
Rezafungin (REZZAYO) FDA-approved for candidemia and invasive candidiasis; ReSTORE Day 30 mortality 23.7% vs 21.3% supports once-weekly IV dosing for patients ≥12 yrs.
Infectious Disease
Ciprofloxacin Guidance for Salmonella Infections and Resistance Considerations
Ciprofloxacin guidance for Salmonella infections: labeled indications, dosing for infectious diarrhea and typhoid fever, resistance data and safety considerations.
Infectious Disease
FDA Approves Ensitrelvir (XOCOVA) for COVID-19 Post‑Exposure Prophylaxis: 67% Reduction in Confirmed Symptomatic COVID-19 in SCORPIO-PEP
Ensitrelvir (XOCOVA) approved for COVID-19 post-exposure prophylaxis; SCORPIO-PEP showed 67% reduction in confirmed symptomatic COVID-19 through Day 10.
Infectious Disease
AREXVY Expanded for Adults 18–59 at Increased RSV Risk
AREXVY (respiratory syncytial virus vaccine, adjuvanted) expanded to include adults 18–59 at increased RSV LRTD risk; single 0.5 mL IM dose; safety includes local reactions and GBS...
Infectious Disease
FDA Expands AREXVY to Adults 18–59 at Increased RSV Risk
AREXVY FDA expands indication to adults 18–59 at increased risk for RSV LRTD; prior adult data showed 82.6% LRTD risk reduction and 94.1% reduction for severe LRTD.
Infectious Disease
FDA Approves zoliflodacin for Uncomplicated Urogenital Gonorrhea: 90.9% Microbiologic Cure
zoliflodacin uncomplicated urogenital gonorrhea: FDA approved Dec 12, 2025; single 3 g oral dose; microbiological cure 90.9% vs 96.2% in Trial 1.
Infectious Disease
FDA Approves doravirine/islatravir for Virologically Suppressed HIV‑1: 1% ≥50 copies/mL
FDA approves doravirine/islatravir (IDVYNSO) for virologically suppressed HIV‑1 in adults; Week 48 trials showed 1% with HIV‑1 RNA ≥50 copies/mL in IDVYNSO arms.
Infectious Disease
REVIVE: Fluvoxamine Reduces Fatigue Severity (−0.43 FSS) vs Placebo
Fluvoxamine long COVID fatigue: REVIVE trial found −0.43 mean FSS reduction vs placebo at day 60; sustained at day 90 (NCT06128967).
Infectious Disease
Nirmatrelvir/Ritonavir Cuts Hospitalization Risk 89% in EPIC-HR
Nirmatrelvir/ritonavir (PAXLOVID) reduced Covid-19 hospitalization/death risk by ~89% in EPIC-HR. Key efficacy, safety, dosing, and prescribing considerations for clinicians.
Infectious Disease
FDA Approves zoliflodacin for Gonorrhea: 90.9% Cure Rate
zoliflodacin (NUZOLVENCE) FDA approval for uncomplicated urogenital gonorrhea: 90.9% microbiologic cure vs 96.2% with ceftriaxone+azithromycin in Trial 1
Infectious Disease
FDA Approves IDVYNSO for Suppressed HIV-1: 1% ≥50 copies/mL
IDVYNSO (doravirine/islatravir) FDA approval for virologically suppressed HIV-1; 1% with HIV-1 RNA ≥50 copies/mL at Week 48 in pivotal trials. doravirine islatravir HIV-1
Infectious Disease
FDA Approves Ensitrelvir for COVID-19 Postexposure Prophylaxis: 67% Reduction in SCORPIO-PEP
Ensitrelvir (XOCOVA) FDA approval for COVID-19 post-exposure prophylaxis: 67% reduction in symptomatic infection in SCORPIO-PEP (adults/adolescents 12+).
Infectious Disease
WHO's 2026 Guidelines: A Comprehensive Approach to Combatting Antimicrobial Resistance
Explore WHO's 2026 guidelines on antimicrobial resistance, focusing on surveillance, infection control, and research investment.
Medical Research
Improve Ovarian Cancer Detection with Personalized Risk Score
Enhance patient outcomes with a cost-effective tool that combines blood test results and age for accurate ovarian cancer detection in women over 50.
Digital Health
Automate 90% of Intake Workflows with AI
Discover how AI-powered automation can streamline post-acute care workflows, freeing staff to focus on patient care and reducing administrative burdens.
Medical Research
Plant-Based Diet Cuts Type 2 Diabetes Risk
Discover how a plant-based diet can lower type 2 diabetes risk while reducing greenhouse gas emissions, benefiting both human and planetary health.
Digital Health
Stay Ahead with Daily Digital Health Updates
Get the latest digital health news, trends, and insights to enhance patient care and stay informed about industry developments and innovations.
Medical Research
Reuse Patient Studies to Cut Drug Dev Costs
Discover how reusing existing patient preference studies can optimize resource allocation and streamline drug development processes, reducing costs and improving efficiency.